Rapt Therapeutics Inc ( (RAPT) ) has released its Q2 earnings. Here is a breakdown of the information Rapt Therapeutics Inc presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases, with a lead drug candidate targeting allergic diseases and an oncology drug candidate in development. In its latest earnings report, RAPT Therapeutics highlighted a net loss of $34.8 million for the first half of 2025, reflecting ongoing research and development expenses. The company reported cash and cash equivalents of $41.9 million and marketable securities worth $127.1 million as of June 30, 2025. RAPT’s strategic focus includes the development of its lead drug candidate, RPT904, and its oncology candidate, tivumecirnon, while exploring partnerships for further development. Looking ahead, RAPT Therapeutics plans to continue its research and development efforts, with management expressing confidence in its current financial position to support operations for the next 12 months.